KUALA LUMPUR, Sept 1 (Bernama) -- Indegene, a technology-led healthcare solutions provider, has announced the acquisition of Medical Marketing Economics LLC (MME), a global leader in Pricing, Reimbursement and Market Access (PRMA) services.
“We are impressed by the MME team’s expertise and growth over the last 20 years. They have vast experience in rare diseases, oncology, orphan drugs, biosimilars and newer technologies like gene therapy and CAR-T. Their 40+ strong team will strengthen our Emerging Biotech and Medical offerings,” said Indegene Co-founder and Chief Executive Officer (CEO), Manish Gupta.
“They bring proven PRMA capabilities that complement our Co-Commercialization solution. We are confident of the value this end-to-end commercialisation capability offers our customers and welcome the MME team to our family.”
Meanwhile, MME Global President and CEO, Jack M. Mycka said: “This partnership gives us access to a larger customer base, a global operations infrastructure, and significant opportunities for growth through adjacent services.”
Life sciences organisations especially emerging Biotech companies offering solutions in rare diseases, increasingly struggle with determining and communicating the optimal market value of their innovations.
MME offers pricing and reimbursement, contracting strategy and tactics, and custom payer market research to address these challenges, according to a statement.
MME’s team brings in a cumulative 300 years of pharma market access, pricing and reimbursement experience and its senior executives have had to make the same decisions as their clients in prior roles.
More details at www.indegene.com.
-- BERNAMA
No comments:
Post a Comment